Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.

ABSTRACT:

Background and aims

Opioid agonist treatment is effective but resource intensive to administer safely in custodial settings, leading to significant under-treatment of opioid dependence in these settings world-wide. This study assessed the safety of subcutaneous slow-release depot buprenorphine in custody.

Design

Open-label, non-randomized trial.

Setting

Correctional centres in New South Wales, Australia.

Participants

Sixty-seven men and women, aged ≥ 18 years of various security classifications with a diagnosis of moderate to severe DSM-5 opioid use disorder currently serving a custodial sentence of ≥ 6 months were recruited between November 2018 and July 2019. Patients not in opioid agonist treatment at recruitment commenced depot buprenorphine; patients alrea

SUBMITTER: Dunlop AJ 

PROVIDER: S-EPMC9291502 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature